Provided by Tiger Trade Technology Pte. Ltd.

Castle Biosciences, Inc.

35.50
+2.066.16%
Post-market: 35.12-0.3780-1.06%19:39 EDT
Volume:519.90K
Turnover:18.26M
Market Cap:1.08B
PE:-54.27
High:35.69
Open:33.64
Low:33.64
Close:33.44
52wk High:44.28
52wk Low:17.72
Shares:30.55M
Float Shares:28.22M
Volume Ratio:2.50
T/O Rate:1.84%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6542
EPS(LYR):-0.8334
ROE:-4.20%
ROA:-1.36%
PB:2.31
PE(LYR):-42.59

Loading ...

Castle Biosciences’ TissueCypher shows improvement in Barrett’s esophagus

TIPRANKS
·
Yesterday

Castle Biosciences publishes DecisionDx-SCC test result study in JAAD

TIPRANKS
·
Sep 10

Castle Biosciences Says JAAD Study Validates Integrated DecisionDx-SCC Test in High-Risk Skin Cancer Cohort of 572 Patients

Reuters
·
Sep 10

SciBase Gets Additional Order from Castle Biosciences

Reuters
·
Sep 08

SciBase Receives Additional Castle Biosciences Order, Expands Collaboration

Reuters
·
Sep 08

Castle Biosciences COO Kristen Oelschlager Reports Disposal of Common Shares Worth $138,510.72

Reuters
·
Sep 04

Castle Biosciences CEO Derek Maetzold Disposes of USD 581,331 in Common Shares

Reuters
·
Sep 02

Castle Biosciences Chief Commercial Officer Juvenal Tobin Sells 9,050 Shares for $317,112.00

Reuters
·
Aug 28

Castle Biosciences to Present at Baird Global Healthcare Conference

Reuters
·
Aug 20

Castle Biosciences CEO Derek Maetzold Sells USD 203,642 of Common Shares

Reuters
·
Aug 19

Castle Biosciences Gets Approval for Dual Listing on Nasdaq Texas

MT Newswires Live
·
Aug 17

Castle Biosciences Approved for Dual Listing on NASDAQ Texas

THOMSON REUTERS
·
Aug 17

Castle Biosciences CEO Derek Maetzold Disposes of 45,016 Common Shares Worth 1.4 Million

Reuters
·
Aug 07

Castle Biosciences CEO Derek Maetzold Reports Disposal of Common Shares Valued at $791,790.26

Reuters
·
Aug 05

Castle Biosciences is Maintained at Buy by BTIG

Dow Jones
·
Aug 03

Castle Biosciences Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Jul 31

Earnings Flash (CSTL) Castle Biosciences Posts Q2 Adjusted EPS -$0.07, vs. FactSet Est of -$0.41

MT Newswires Live
·
Jul 31

Castle Biosciences reports Q2 EPS (7c), consensus (41c)

TIPRANKS
·
Jul 31

Castle Biosciences Q2 FY26 Net Loss Widens to $2.1 Million; Revenue Rises 20.1% to $103.5 Million

Reuters
·
Jul 31

Castle Biosciences Q2 Adj. EPS $(0.07) Beats $(0.41) Estimate, Sales $103.546M Beat $86.240M Estimate

Benzinga Earnings
·
Jul 31